<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Cirrhosis%2Fen</id>
	<title>Cirrhosis/en - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Cirrhosis%2Fen"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Cirrhosis/en&amp;action=history"/>
	<updated>2026-04-19T13:53:09Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=Cirrhosis/en&amp;diff=380872&amp;oldid=prev</id>
		<title>FuzzyBot: Updating to match new version of source page</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Cirrhosis/en&amp;diff=380872&amp;oldid=prev"/>
		<updated>2026-01-07T14:44:38Z</updated>

		<summary type="html">&lt;p&gt;Updating to match new version of source page&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Página nueva&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Background==&lt;br /&gt;
&lt;br /&gt;
*A generally irreversible fibrotic scarring of the liver parenchyma resulting in liver failure&lt;br /&gt;
*The twelfth leading cause of death in men and women in 2013&amp;lt;ref&amp;gt;Heron M. Deaths: Leading Causes for 2013. Natl Vital Stat Rep 2016: 16;65(2):1-95.&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Causes===&lt;br /&gt;
&lt;br /&gt;
*[[Special:MyLanguage/Hepatitis|Hepatitis]] chronic B and C&lt;br /&gt;
*Alcoholic liver disease&lt;br /&gt;
*[[Special:MyLanguage/Non-alcoholic steatohepatitis|Non-alcoholic steatohepatitis]]&lt;br /&gt;
*Drug induced (ie. [[Special:MyLanguage/Tylenol|Tylenol]]. [[Special:MyLanguage/amiodarone|amiodarone]], NRTIs])&lt;br /&gt;
*[[Special:MyLanguage/Congestive heart failure (CHF)|Cardiac Cirrhosis]]&lt;br /&gt;
*Primary biliary cirrhosis&lt;br /&gt;
*[[Special:MyLanguage/Primary sclerosing cholangitis|Primary sclerosing cholangitis]]&lt;br /&gt;
*[[Special:MyLanguage/Autoimmune hepatitis|Autoimmune hepatitis]]&lt;br /&gt;
*Alpha1 anti-trypsin Deficiency&lt;br /&gt;
*[[Special:MyLanguage/Cystic Fibrosis|Cystic Fibrosis]]&lt;br /&gt;
&lt;br /&gt;
{{Sites of Portalcaval Anastomosis}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Clinical Features==&lt;br /&gt;
&lt;br /&gt;
[[File:Jaundice08.jpg|thumb|Jaundice of the skin]]&lt;br /&gt;
[[File:SpiderAngioma.jpg|thumb|Spider angioma]]&lt;br /&gt;
[[File:Hepaticfailure.jpg|thumb|[[Special:MyLanguage/Ascites|Ascites]] secondary to cirrhosis.]]&lt;br /&gt;
*May be asymptomatic initially&lt;br /&gt;
*Malaise, [[Special:MyLanguage/weakness|weakness]] (from [[Special:MyLanguage/electrolyte derangements|electrolyte derangements]])&lt;br /&gt;
*[[Special:MyLanguage/Abdominal pain|Abdominal pain]]&lt;br /&gt;
*[[Special:MyLanguage/Ascites|Ascites]], [[Special:MyLanguage/SBP|SBP]] (fever, abdominal tenderness)&lt;br /&gt;
*[[Special:MyLanguage/Altered mental status|Altered mental status]] due to [[Special:MyLanguage/hepatic encephalopathy|hepatic encephalopathy]]&lt;br /&gt;
*[[Special:MyLanguage/liver disease induced coagulopathy|Coagulopathy]]&lt;br /&gt;
*[[Special:MyLanguage/GI bleed|GI bleed]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Differential Diagnosis==&lt;br /&gt;
&lt;br /&gt;
{{DDX abdominal distention}}&lt;br /&gt;
&lt;br /&gt;
{{Hepatomegaly DDX}}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Evaluation==&lt;br /&gt;
&lt;br /&gt;
[[File:Auscities.png|thumb|Ascites appearance on ultrasound]]&lt;br /&gt;
[[File:CirrhosisWithAscitesMark.png|thumb|Liver cirrhosis with ascites on CT]]&lt;br /&gt;
&lt;br /&gt;
===Workup===&lt;br /&gt;
&lt;br /&gt;
*CBC&lt;br /&gt;
*Chem 7&lt;br /&gt;
*PT/PTT&lt;br /&gt;
*[[Special:MyLanguage/LFTs|LFTs]] + lipase&lt;br /&gt;
*[[Special:MyLanguage/FAST|FAST]]&lt;br /&gt;
**See workup, if positive for [[Special:MyLanguage/ascites|ascites]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Diagnosis===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Management==&lt;br /&gt;
&lt;br /&gt;
'''Complications of cirrhosis'''&lt;br /&gt;
*[[Special:MyLanguage/Ascites|Ascites]]&lt;br /&gt;
*Esophageal [[Special:MyLanguage/varices|varices]]&lt;br /&gt;
*[[Special:MyLanguage/Hepatic encephalopathy|Hepatic encephalopathy]]&lt;br /&gt;
*[[Special:MyLanguage/Spontaneous bacterial peritonitis|Spontaneous bacterial peritonitis]]&lt;br /&gt;
*[[Special:MyLanguage/Hepatorenal syndrome|Hepatorenal syndrome]]&lt;br /&gt;
*Portal hypertension&lt;br /&gt;
*[[Special:MyLanguage/Upper gastrointestinal bleed|Upper gastrointestinal bleed]]&lt;br /&gt;
*[[Special:MyLanguage/Hepatocellular carcinoma|Hepatocellular carcinoma]]&lt;br /&gt;
&lt;br /&gt;
'''Pain management in cirrhotic patients'''&lt;br /&gt;
*[[Special:MyLanguage/Acetaminophen|Acetaminophen]] is safe for short-term use at reduced dose of 2 grams total per day&lt;br /&gt;
*[[Special:MyLanguage/Gabapentin|Gabapentin]] or [[Special:MyLanguage/pregabalin|pregabalin]] for neuropathic pain&lt;br /&gt;
*Avoid [[Special:MyLanguage/NSAIDs|NSAIDs]] &lt;br /&gt;
*Avoid [[Special:MyLanguage/opioids|opioids]] &lt;br /&gt;
**unpredictable effects if liver function impaired due to hepatic metabolism&lt;br /&gt;
**if necessary, [[Special:MyLanguage/fentanyl|fentanyl]] or [[Special:MyLanguage/tramadol|tramadol]] probably safest&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Disposition==&lt;br /&gt;
&lt;br /&gt;
*Often complex and should be based on presence/absence of acute complications&lt;br /&gt;
*If no complications present, discussion with patient's primary care provider or gastroenterologist recommended&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Prognosis==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===Child-Pugh Score[http://www.mdcalc.com/child-pugh-score-for-cirrhosis-mortality/ &amp;lt;ref&amp;gt;Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64&amp;lt;/ref&amp;gt;]===&lt;br /&gt;
&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
!  !! +1 !! +2 !! +3&lt;br /&gt;
|-&lt;br /&gt;
| Bilirubin|| &amp;lt;2mg/dL || 2-3mg/dL || &amp;gt;3 Mg/dL&lt;br /&gt;
|-&lt;br /&gt;
| Albumin || &amp;gt;3.5mg/dL || 2.8-3.5mg/dL || &amp;lt;2.8mg/dL&lt;br /&gt;
|-&lt;br /&gt;
| INR || &amp;lt;1.7 || 1.7-2.2 || &amp;gt;2.2&lt;br /&gt;
|-&lt;br /&gt;
|Ascites || No ascites || Ascites, medically controlled || Ascites, poorly controlled&lt;br /&gt;
|-&lt;br /&gt;
| Encephalopathy || No encephalopathy || Encephalopathy, medically controlled || Encephalopathy, poorly controlled&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
*Score ≤ 7 = Class A = 100% and 85% one and two-year patient survival&lt;br /&gt;
*Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival&lt;br /&gt;
*Score ≥ 10 = Class c = 45% and 35% one and two-year patient survival&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===MELD Score[http://www.mdcalc.com/meld-score-model-for-end-stage-liver-disease-12-and-older/ &amp;lt;ref&amp;gt;Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.&amp;lt;/ref&amp;gt;]===&lt;br /&gt;
&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
! MELD-Na Score !! 3-month mortality&lt;br /&gt;
|-&lt;br /&gt;
| 40 || 71.3%&lt;br /&gt;
|-&lt;br /&gt;
| 30-39 || 52.6%&lt;br /&gt;
|-&lt;br /&gt;
| 20-29 || 19.6%&lt;br /&gt;
|-&lt;br /&gt;
| 10-19 || 6.0%&lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;9 || 1.9%&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==See Also==&lt;br /&gt;
&lt;br /&gt;
*[[Special:MyLanguage/Viral hepatitis|Viral hepatitis]]&lt;br /&gt;
*[[Special:MyLanguage/Acute hepatic failure|Acute hepatic failure]]&lt;br /&gt;
*[[Special:MyLanguage/Jaundice|Jaundice]]&lt;br /&gt;
*[[Special:MyLanguage/Ascites|Ascites]]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==External Links==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category:GI]]&lt;/div&gt;</summary>
		<author><name>FuzzyBot</name></author>
	</entry>
</feed>